SCHEMBL1179544

SCHEMBL1179544

O=C(O)c1cc(-c2ccc3cc(O)ccc3c2)ccn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.57
ESR1 P03372 8/20 0.53
ESR2 Q92731 8/20 0.53
ABL1 P00519 1/20 0.50
ABCB1 P08183 1/20 0.50
BCR P11274 1/20 0.50
CYP11B1 P15538 2/20 0.49
CYP11B2 P19099 2/20 0.49
CYP19A1 P11511 1/20 0.49
FTO Q9C0B1 3/20 0.49
HSD17B1 P14061 2/20 0.49
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
CYP3A4 P08684 2/20 0.49
KDM6B O15054 1/20 0.49
TET3 O43151 1/20 0.49
KDM4A O75164 1/20 0.49
BBOX1 O75936 1/20 0.49
MAPT P10636 1/20 0.49
KDM5A P29375 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9939518 0.82 FTO (0.53) ESR1ESR2ABL1ABCB1BCR
SCHEMBL7513922 0.82 KMO (0.71) KMOFTOKDM4EALDH1A1KDM6B
SCHEMBL30800092 0.82 KMO (0.71) KMOFTOKDM4EALDH1A1KDM6B
SCHEMBL1180030 0.81 FTO (0.52) ESR1ESR2ABL1ABCB1BCR
SCHEMBL1179325 0.80 KDM4E (0.53) KMOCYP11B1CYP11B2CYP19A1HSD17B1
SCHEMBL3642765 0.79 KMO (0.56) KMOCYP19A1FTOHSD17B1KDM4E
SCHEMBL65841 0.78 KDM4E (0.63) KMOFTOKDM4EALDH1A1KDM6B
SCHEMBL29951101 0.78 KDM4E (0.63) KMOFTOKDM4EALDH1A1KDM6B
SCHEMBL21200187 0.77 MEN1 (0.43) ESR1ESR2ABL1FTOHSD17B1
SCHEMBL9938365 0.77 FTO (0.58) ESR1ESR2ABL1ABCB1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651871-A1 NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS N30 Pharmaceuticals, Inc. (US) 2013-10-23 EP disclosed
WO-2012083171-A1 NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS N30 PHARMACEUTICALS, LLC (US) 2012-06-21 WO disclosed
US-20110034507-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2011-02-10 US disclosed
CN-101877966-A Farnesoid X receptor agonists SMITHKLINE BEECHAM CORP 2010-11-03 CN disclosed
EP-2173174-A1 FARNESOID X RECEPTOR AGONISTS GlaxoSmithKline LLC (US) 2010-04-14 EP disclosed
WO-2009005998-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034507-A1 FARNESOID X RECEPTOR AGONISTS NR1H4, NR1H3, NR1H2 KMO 2002/4885ESR1 915/4885ESR2 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.